{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:13:22Z","timestamp":1759936402415,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"am","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.therap.2020.02.014","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T11:37:43Z","timestamp":1581593863000},"page":"221-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Patients\u2019 organizations in rare diseases and involvement in drug information: Illustrations with LMC France, the French Association of Chronic Myeloid leukemia"],"prefix":"10.1016","volume":"75","author":[{"given":"Mina","family":"Daban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mence","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9629","key":"10.1016\/j.therap.2020.02.014_bib0130","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/S0140-6736(08)60875-2","article-title":"Empowerment of patients: lessons from the rare diseases community","volume":"371","author":"Aym\u00e9","year":"2008","journal-title":"Lancet"},{"year":"2017","series-title":"The added value of patients\u2019 organizations","author":"European patients Forum","key":"10.1016\/j.therap.2020.02.014_bib0135"},{"issue":"1","key":"10.1016\/j.therap.2020.02.014_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2796.2006.01666.x","article-title":"A journey of hope: lessons learned from studies on rare diseases and orphan drugs","volume":"260","author":"W\u00e4stfelt","year":"2006","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.therap.2020.02.014_bib0145","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/fcp.12314","article-title":"Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology","volume":"31","author":"Micallef","year":"2017","journal-title":"Fundam Clin Pharmacol"},{"year":"2011","series-title":"Patients\u2019priorities and needs for rare disease research 2014\u20132020","author":"Eurordis","key":"10.1016\/j.therap.2020.02.014_bib0150"},{"issue":"3","key":"10.1016\/j.therap.2020.02.014_bib0155","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.therap.2020.02.014_bib0160","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2015.139337","article-title":"Chronic myeloid Leukemia: reminiscences and dreams","volume":"101","author":"Mughal","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.therap.2020.02.014_bib0165","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.therap.2020.02.014_bib0170","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1111\/bcp.14092","article-title":"Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities\u00a0\u2014\u00a0Which TKI is the safest?","volume":"85","author":"E\u015fkazan","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2020.02.014_bib0175","series-title":"Risque d\u2019hypertension art\u00e9rielle pulmonaire chez les patients trait\u00e9s par Sprycel\u00ae (dasatinib)","article-title":"Lettre aux professionnels de sant\u00e9","author":"ANSM","year":"2011"},{"issue":"3","key":"10.1016\/j.therap.2020.02.014_bib0180","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2515\/therapie\/2010017","article-title":"Therapeutic drug monitoring of tyrosine-kinase inhibitors in the treatment of chronic myelogenous leukaemia: interests and limits","volume":"65","author":"Bouchet","year":"2010","journal-title":"Therapie"},{"year":"2019","series-title":"Association LMC France","key":"10.1016\/j.therap.2020.02.014_bib0185"},{"year":"2019","series-title":"CML Advocates Network For Chronic Myeloid Leukemia Patient Group Advocates","key":"10.1016\/j.therap.2020.02.014_bib0190"},{"year":"2019","series-title":"World CML Day","key":"10.1016\/j.therap.2020.02.014_bib0195"},{"year":"2013","series-title":"Livre blanc des 1ers \u00e9tats g\u00e9n\u00e9raux de la leuc\u00e9mie my\u00e9lo\u00efde chronique","author":"LMC-France","key":"10.1016\/j.therap.2020.02.014_bib0200"},{"year":"2016","series-title":"Livre blanc des 2\u00e8mes \u00e9tats g\u00e9n\u00e9raux de la leuc\u00e9mie my\u00e9lo\u00efde chronique","author":"LMC-France","key":"10.1016\/j.therap.2020.02.014_bib0205"},{"year":"2019","series-title":"La e-universit\u00e9 LMC France","author":"LMC-France","key":"10.1016\/j.therap.2020.02.014_bib0210"},{"year":"2013","series-title":"Journ\u00e9e d\u2019informations et d\u2019\u00e9changes ANSM- avec les associations de patients","author":"LMC France","key":"10.1016\/j.therap.2020.02.014_bib0215"},{"year":"2019","series-title":"Les fiches LMC France","author":"LMC France","key":"10.1016\/j.therap.2020.02.014_bib0220"},{"key":"10.1016\/j.therap.2020.02.014_bib0225","unstructured":"Bulletin de pharmacovigilance Marseille et Nice 2018. https:\/\/www.rfcrpv.fr\/wp-content\/uploads\/2018\/02\/pharmacovigilance-26-interactif.pdf [Accessed January 20, 2020 (12 pp.)]."},{"year":"2016","series-title":"Essais cliniques et m\u00e9dicaments dans la vraie vie. Journ\u00e9e mondiale de la LMC","author":"Micallef","key":"10.1016\/j.therap.2020.02.014_bib0230"},{"key":"10.1016\/j.therap.2020.02.014_bib0235","unstructured":"Micallef J. Les m\u00e9dicaments g\u00e9n\u00e9riques; 2019. https:\/\/www.lmc-france.fr\/vid%C3%A9os\/les-vid%C3%A9os-%C3%A9ducationnelles\/. [Accessed January 20, 2020]."},{"issue":"6","key":"10.1016\/j.therap.2020.02.014_bib0240","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40264-014-0162-y","article-title":"Adverse drug reaction reporting by patients: an overview of fifty countries","volume":"37","author":"Margraff","year":"2014","journal-title":"Drug Saf"},{"issue":"7","key":"10.1016\/j.therap.2020.02.014_bib0245","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00432-017-2372-z","article-title":"Factors influencing adherence in CML and ways to improvement: results of a patient-driven survey of 2546 patients in 63 countries","volume":"143","author":"Geissler","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"year":"2019","series-title":"LMC coach","author":"LMC","key":"10.1016\/j.therap.2020.02.014_bib0250"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720300196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720300196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:52:53Z","timestamp":1758567173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720300196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0040595720300196"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.02.014","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients\u2019 organizations in rare diseases and involvement in drug information: Illustrations with LMC France, the French Association of Chronic Myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}